<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CORTISPORIN- neomycin sulfate, polymyxin b sulfate and hydrocortisone acetate cream </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<h1>CORTISPORIN<span class="Sup">®</span> Cream<br>(neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b76895e2-81c8-4760-9f9e-5eb69681491b"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP) is a topical antibacterial cream. Each gram contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone acetate 5 mg (0.5%). The inactive ingredients are liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, purified water, and 0.25% methylparaben added as a preservative. Sodium hydroxide or sulfuric acid may be added to adjust pH.</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of <span class="Italics">Streptomyces fradiae</span> Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 µg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are:</p>
<div class="Figure"><img alt="Chem structure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e492b2b0-ad73-4866-c996-a1fcb12dbcad&amp;name=cortisporin-01.jpg"></div>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span>, which are produced by the growth of <span class="Italics">Bacillus polymyxa</span> (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are:</p>
<div class="Figure"><img alt="chem structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e492b2b0-ad73-4866-c996-a1fcb12dbcad&amp;name=cortisporin-02.jpg"></div>
<p>Hydrocortisone acetate is the acetate ester of hydrocortisone, an anti-inflammatory hormone. Its chemical name is 21-(acetyloxy)- 11β,17-dihydroxypregn-4-ene-3,20-dione. Its structural formula is:</p>
<div class="Figure"><img alt="Chem structure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e492b2b0-ad73-4866-c996-a1fcb12dbcad&amp;name=cortisporin-03.jpg"></div>
<p>The base is a smooth vanishing cream with a pH of approximately 5.0.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_02c22d78-a9ca-4490-9737-1789d313c4cc"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Corticoids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.</p>
<p>The anti-infective components in the combination are included to provide action against specific organisms susceptible to them. Polymyxin B sulfate and neomycin sulfate together are considered active against the following microorganisms: <span class="Italics">Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella- Enterobacter </span> species, <span class="Italics">Neisseria</span> species, and<span class="Italics"> Pseudomonas aeruginosa</span>. The product does not provide adequate coverage against <span class="Italics">Serratia marcescens</span> and streptococci, including <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p>The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.</p>
<p>The acid pH helps restore normal cutaneous acidity. Owing to its excellent spreading and penetrating properties, the cream facilitates treatment of hairy and intertriginous areas. It may also be of value in selective cases where the lesions are moist.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_efc99d1c-d2d0-472a-9a75-4e7e52724e45"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For the treatment of corticosteroid-responsive dermatoses with <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment (see <a href="#i4i_warnings_id_a1e51390-4e79-4540-bf7c-bd92e3cdc32f">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_dffeffd5-69fd-4d76-b6c1-7422bf9de116"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Not for use in the eyes or in the external ear canal if the eardrum is perforated. This product is contraindicated in tuberculous, fungal, or viral lesions of the skin (herpes simplex, <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>). This product is contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_a1e51390-4e79-4540-bf7c-bd92e3cdc32f"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Because of the concern of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> associated with neomycin, this combination should not be used over a wide area or for extended periods of time.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_949a789c-6e7f-4e8a-ac89-b29677a70774"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_20fe48e0-982c-451c-b8ab-9b3e85100684"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">As with any antibacterial preparation, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Appropriate measures should be taken if this occurs. Use of steroids on infected areas should be supervised with care as anti-inflammatory steroids may encourage spread of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If this occurs, steroid therapy should be stopped and appropriate anti-bacterial drugs used. Generalized dermatological conditions may require systemic corticosteroid therapy.</p>
<p>Signs and symptoms of exogenous <span class="product-label-link" type="condition" conceptid="438123" conceptname="Adrenocortical hyperfunction">hyperadrenocorticism</span> can occur with the use of topical corticosteroids, including adrenal suppression. Systemic absorption of topically applied steroids will be increased if extensive body surface areas are treated or if occlusive dressings are used. Under these circumstances, suitable precautions should be taken when long-term use is anticipated.</p>
<p>Specifically, sufficient percutaneous absorption of hydrocortisone can occur in pediatric patients during prolonged use to cause cessation of growth, as well as other systemic signs and symptoms of <span class="product-label-link" type="condition" conceptid="438123" conceptname="Adrenocortical hyperfunction">hyperadrenocorticism</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ed6a30fc-9102-4e1d-afb7-7347fde3c0eb"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, irritation, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists or increases, discontinue use and notify physician. Do not use in the eyes.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_8cb6650b-3db6-49c3-a7bb-ea0c0a535206"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_b0cb766b-2c57-4702-98fe-eb5ec5dce64a"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Longterm studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity attributable to oral administration of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_96098d40-1323-4e92-bece-3659a7e667c3"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_d5f3117e-4373-49cb-8b0d-4d4e33a784fd"></a><a name="section-6.5.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Teratogenic Effects</span></span></h3>
<p class="First">Pregnancy Category C. Corticosteroids have been shown to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d8710689-9571-46af-a95b-92e7c92d076e"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Hydrocortisone acetate appears in human milk following oral administration of the drug. Since systemic absorption of hydrocortisone may occur when applied topically, caution should be exercised when CORTISPORIN Cream is used by a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_6c883e4c-4c4e-456c-a820-09ede7be2293"></a><a name="section-6.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Cortisporin Cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_06b3dd2d-3419-4800-b842-607251f837e0"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established (see <a href="#i4i_precautions_general_id_20fe48e0-982c-451c-b8ab-9b3e85100684">PRECAUTIONS: General</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_93c16071-65df-4efc-9c6b-476d467312f1"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Neomycin occasionally causes skin sensitization. <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> have also been reported (see <a href="#i4i_warnings_id_a1e51390-4e79-4540-bf7c-bd92e3cdc32f">WARNINGS</a>). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span> occurred in two of 2,175 (0.09%) individuals in the general population.<span class="Sup">1</span> In another study, the incidence was found to be approximately 1%.<span class="Sup">2</span></p>
<p>The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, maceration of the skin, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>.</p>
<p>When steroid preparations are used for long periods of time in intertriginous areas or over extensive body areas, with or without occlusive non-permeable dressings, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span> may occur; also there exists the possibility of systemic side effects when steroid preparations are used over large areas or for a long period of time.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_0d4d2491-db96-45a7-adf5-fc28fb4b12b7"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">A small quantity of the cream should be applied 2 to 4 times daily, as required. The cream should, if conditions permit, be gently rubbed into the affected areas.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_960fedc3-d407-4863-9488-5b4de52a3168"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Tube of 7.5 g (<span class="Bold">NDC</span> 61570-032-75). </p>
<p><span class="Bold">Store at 15° to 25°C (59° to 77°F).</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_a69183c2-f551-4718-85be-17732165d283"></a><a name="section-10"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Leyden JJ, Kligman AM. <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span> to neomycin sulfate. <span class="Italics">JAMA</span>. 1979;242:1276-1278.</li>
<li>Prystowsky SD, Allen AM, Smith RW, et al. Allergic contact <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nickel, neomycin, ethylenediamine, and benzocaine. <span class="Italics">Arch Dermatol</span>. 1979;115:959-962.</li>
</ol>
<p class="First">Prescribing Information as of November 2003. </p>
<p>Distributed by: Monarch Pharmaceuticals, Inc., Bristol, TN 37620 </p>
<p>(A wholly owned subsidiary of King Pharmaceuticals, Inc.) </p>
<p>Manufactured by: King Pharmaceuticals, Inc., Bristol, TN 37620</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 7.5 g Tube Label</h1>
<p class="First">NDC 61570-032-75</p>
<p><span class="Bold Italics">Pfizer <br></span><span class="Bold">Cortisporin</span><span class="Sup">®</span><span class="Bold"> Cream <br></span>(neomycin and polymyxin B sulfates and<br>hydrocortisone acetate cream, USP) <br><span class="Bold">7.5 g</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Each gram contains neomycin sulfate equivalent to 3.5 mg<br>neomycin base, polymyxin B sulfate equivalent to 10,000<br>polymyxin B units, hydrocortisone acetate 5 mg (0.5%), and<br>methylparaben 0.25% (added as a preservative).</p>
<div class="Figure"><img alt="Principal Display Panel - 7.5 g Tube Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e492b2b0-ad73-4866-c996-a1fcb12dbcad&amp;name=cortisporin-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 7.5 g Tube Carton</h1>
<p class="First">NDC 61570-032-75</p>
<p><span class="Bold Italics">Pfizer <br></span><span class="Bold">Cortisporin<span class="Sup">®</span> Cream</span><br> (neomycin and polymyxin B sulfates and<br>hydrocortisone acetate cream, USP) <br><span class="Bold">7.5 g</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 7.5 g Tube Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e492b2b0-ad73-4866-c996-a1fcb12dbcad&amp;name=cortisporin-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CORTISPORIN 		
					</strong><br><span class="contentTableReg">neomycin sulfate, polymyxin b sulfate, and hydrocortisone acetate cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61570-032</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">3.5 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B</td>
<td class="formItem">10000 [iU]  in 1 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCORTISONE ACETATE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE ACETATE</td>
<td class="formItem">5 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61570-032-75</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">7.5 g in 1 TUBE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050218</td>
<td class="formItem">06/10/1963</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4b6940b2-b2da-42b9-9ca0-7148e80b6c4d</div>
<div>Set id: e492b2b0-ad73-4866-c996-a1fcb12dbcad</div>
<div>Version: 6</div>
<div>Effective Time: 20150417</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
